Clinical trials: Omega-3 Fatty Acids
Non-Alcoholic Fatty Liver Disease
Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management.
- Trial name
- WELCOME (NCT00760513)
- Testing
- OMACOR
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Parenteral Nutrition Associated Liver Disease
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
Babies in the newborn intensive care unit who are dependent upon intravenous nutrition for a long period of time frequently develop liver damage. The fat used is called intralipid and is made from soybean oil.
- Trial name
- NCT00862446
- Testing
- Omegaven
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University Medical Center
Hyperlipidemia
Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters
The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical…
- Trial name
- NCT02153073
- Testing
- Omega-3 fatty acid ethyl esters
- Where
- 2 sites in Japan
- Volunteers
- 3,084 people
- Sponsor
- Takeda
Pediatric Bipolar Spectrum Disorders
Inositol and Omega-3 Fatty Acids in Pediatric Mania
The purpose of this study is to a) evaluate the efficacy of omega-3 fatty acids versus inositol in the treatment of pediatric bipolar disorder, b) evaluate the efficacy of omega-3 fatty acid plus inositol in the treatment of…
- Trial name
- NCT01396486
- Testing
- Omega-3, Inositol
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital
Metabolic Diseases, Endocrine System Diseases
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD.
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases
- Trial name
- NCT00935766
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Denver Health and Hospital Authority
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of…
- Trial name
- NCT00845845
- Testing
- Omega-3-acid ethyl esters (Lovaza)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Myocardial Infarction, Death, Sudden, Cardiac
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack.
- Trial name
- OmegaREMODEL (NCT00729430)
- Testing
- Omega-3 Fatty Acids (Fish Oil Supplements)
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Aromatase inhibitor medications have been approved by the U.S Food and Drug Administration (FDA) for treatment of hormone receptor positive breast cancer.
- Trial name
- ALTA (NCT04268134)
- Testing
- Omega-3 fatty acid supplement
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan Rogel Cancer Center
Depression
Omega-3 for Depression and Other Cardiac Risk Factors - 2
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for…
- Trial name
- Omega-3(2) (NCT02021669)
- Testing
- Omega-3 supplement
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Autism
Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders
Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in…
- Trial name
- NCT00467818
- Testing
- Omega 3 fatty acids
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Attention Deficit/Hyperactivity Disorder (ADHD)
The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD.
- Trial name
- NCT00418184
- Testing
- Phosphatidylserine-Omega3, Colored cellulose tainted with fishy odor
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Enzymotec
Heart Failure, Gastrointestinal Bleeding
Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
This study evaluates the efficacy of high-dose fish oil in decreasing rates of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.
- Trial name
- NCT03784963
- Testing
- Omega 3 fatty acids
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Exudative Age Related Macular Degeneration
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patients receiving intravitreal…
- Trial name
- NCT01819415
- Testing
- Anti-VEGF plus AREDS-2, Anti-VEGF plus AREDS-1
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Sarcopenia, Dynapenia
Omega-3 Supplementation and Resistance Training
The purpose of this project is to evaluate whether omega-3 fatty acid supplementation (combined eicosapentaenoic acid and docosahexaenoic acid [EPA/DHA] supplement) augments the effects of a 12-week resistance training program in…
- Conditions
- Sarcopenia, Dynapenia, Inflammation
- Trial name
- NCT02617511
- Testing
- Omega-3 Supplementation
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Obesity, Insulin Resistance
Intervention Study With Omega-3 Fatty Acids for Weight Loss and Insulin Resistance in Adolescents
The purpose of this study is to evaluate if a supplement containing omega-3 long chain polyunsaturated fatty acids for three months reduce obesity and insulin resistance to obese adolescents if administered together with a…
- Trial name
- O3WLIRADOL (NCT01456221)
- Testing
- Omega3 and an hypocaloric diet., Sunflower oil with an hypocaloric diet.
- Where
- Mexico
- Volunteers
- 366 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Whole Body Energy Metabolism
Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate
Fatty acids are the main components of the cell membranes. It has been demonstrated that diet can alter the characteristics and function of many membranes in the body, which has an effect on cardiovascular and metabolic health.
- Trial name
- NCT02092649
- Testing
- Omega-3 Complete
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Guelph
Obesity
Fish Oils and Adipose Inflammation Reduction
This study is a clinical trial designed to assess whether fish oil treatments are effective in the prevention of obesity-related fat tissue (adipose) inflammation.
- Trial name
- FAIR (NCT02010359)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
History of Myocardial Infarction, Hypertriglyceridemia
A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy
A prospective observational program using digital technology tools to enhance patient adherence to Omacor therapy
- Trial name
- DIAPAsOn (NCT03415152)
- Testing
- Omacor (Omega-3-acid ethyl esters)
- Where
- 93 sites in Russia
- Volunteers
- 3,000 people
- Sponsor
- Abbott